Affinity purification of human alpha galactosidase utilizing a novel small molecule biomimetic of alpha-D-galactose
Open Access
- 1 January 2021
- journal article
- research article
- Published by Elsevier in Protein Expression and Purification
- Vol. 177, 105752
Abstract
No abstract availableKeywords
Funding Information
- Takeda Pharmaceuticals
This publication has 18 references indexed in Scilit:
- Molecular Basis of 1-Deoxygalactonojirimycin Arylthiourea Binding to Human α-Galactosidase A: Pharmacological Chaperoning Efficacy on Fabry Disease MutantsACS Chemical Biology, 2014
- Preparative Purification of Recombinant Proteins: Current Status and Future TrendsBioMed Research International, 2013
- Prevalence of symptoms in female Fabry disease patients: a case‐control surveyJournal of Inherited Metabolic Disease, 2012
- The Molecular Basis of Pharmacological Chaperoning in Human α-GalactosidaseChemistry & Biology, 2011
- Fabry Disease – Current Treatment and New Drug DevelopmentCurrent Chemical Genomics, 2010
- Catalytic Mechanism of Human α-GalactosidaseJournal of Biological Chemistry, 2010
- The Pharmacological Chaperone 1-Deoxygalactonojirimycin Reduces Tissue Globotriaosylceramide Levels in a Mouse Model of Fabry DiseaseMolecular Therapy, 2010
- Effects of pH and Iminosugar Pharmacological Chaperones on Lysosomal Glycosidase Structure and StabilityBiochemistry, 2009
- Natural history of Fabry disease in females in the Fabry Outcome SurveyJournal of Medical Genetics, 2005
- Accelerated transport and maturation of lysosomal α–galactosidase A in Fabry lymphoblasts by an enzyme inhibitorNature Medicine, 1999